<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596996</url>
  </required_header>
  <id_info>
    <org_study_id>1608M92324</org_study_id>
    <nct_id>NCT03596996</nct_id>
  </id_info>
  <brief_title>Optimizing Iron Status While Minimizing Morbidity in HIV-infected Ugandan Children</brief_title>
  <official_title>Optimizing Iron Status While Minimizing Morbidity in HIV-infected Ugandan Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Joint Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo-controlled trial of the effect of 84 days of daily iron supplementation&#xD;
      on iron status, gut microbiome profile, infectious disease frequency, and HIV disease&#xD;
      severity in moderately anemic [hemoglobin 9 - &lt;11 g/dL (6-59 mo); hemoglobin 9 - &lt; 11.5 g/dL&#xD;
      (5 -12 years)], HIV-infected Ugandan children between the ages of 6 mos and 12 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">February 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anemia</measure>
    <time_frame>3 months</time_frame>
    <description>Prevalence of anemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Iron status</measure>
    <time_frame>3 months</time_frame>
    <description>Iron status measured using ferritin, sTfR, CRP and hepcidin concentration in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sick Child Visits</measure>
    <time_frame>3 months</time_frame>
    <description>Number of acute illnesses leading to visit to healthcare provider</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary iron absorption</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of 57Fe from oral dose that is incorporated into hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV virologic control</measure>
    <time_frame>3 month</time_frame>
    <description>HIV viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV related immunosuppression</measure>
    <time_frame>3 months</time_frame>
    <description>CD4 count</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Microbiome gut profile</measure>
    <time_frame>3 months</time_frame>
    <description>Ratio of Enterobacteriaceae to Lactobacillaceae and Bifidobacteriaceae</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Anemia</condition>
  <condition>Iron-deficiency</condition>
  <condition>Iron Deficiency Anemia</condition>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>Ferrous Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 6 to 23 months of age will receive a tablet that contains the equivalent of 12.5 mg of elemental iron. Children over 24 months will receive a tablet that contains the equivalent of 30 mg of elemental iron.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferrous Sulfate</intervention_name>
    <description>Ferrous sulfate dosed by WHO guidelines by age for the prevention of iron deficiency and anemia.</description>
    <arm_group_label>Ferrous Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with identical appearance comparison intervention arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of HIV (based JCRC clinic records);&#xD;
&#xD;
          2. On Highly Active Antiretroviral Treatment (HAART) for ≥ 6 months&#xD;
&#xD;
          3. Age 6 months - 12 years at the time of screening&#xD;
&#xD;
          4. Hemoglobin 9 - &lt;11 g/dL (6-59 mo); hemoglobin 9 - &lt; 11.5 g/dL (5 -12 years)by CBC at&#xD;
             time of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute illness or current opportunistic infection&#xD;
&#xD;
          2. Temperature &gt;= 38.0°C at the time of screening&#xD;
&#xD;
          3. Known sickle cell disease&#xD;
&#xD;
          4. Acute malnutrition (bilateral pitting edema or extreme wasting)&#xD;
&#xD;
          5. Any chronic illness requiring regular medical attention&#xD;
&#xD;
          6. Residence &gt; 50 km from JCRC hospital&#xD;
&#xD;
          7. Non-English or Luganda speaking&#xD;
&#xD;
          8. Currently taking iron supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Cusick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joint Clinical Research Centre</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be available on request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>IPD used for the current study are available after publication of primary findings on reasonable request. Requests may be subject to review by Joint Clinical Research Centre in Kampala, Uganda to determine if aims and analysis are consistent with participant consent.</ipd_time_frame>
    <ipd_access_criteria>Joint Clinical Research Centre review to determine if aims and analysis on consistent with participant consent.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

